Global Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Research Report 2022

Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Causal organism for infectious diseases could be bacteria, viruses, parasites or fungi and can be spread, directly or indirectly, from one person to another. Molecular diagnostic is showing promise in the identification of microorganisms as well as evaluation of virulence factors and antibiotic resistance determinants. Molecular infectious diseases diagnosis is moving towards high-throughput, simple, array-type technologies that provide a wealth of data on types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. Molecular diagnostic helping infectious diseases to be more accurately and effectively treated.
Due to the COVID-19 pandemic, the global Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Pcr accounting for % of the Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment include Cepheid, Beckton Dickinson, Gen Probe (Hologic), Qiagen, Roche, Bayer Healthcare, Dako, Abbott Laboratories and Danaher, etc. In terms of revenue, the global 3 largest players have a % market share of Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment in 2021.
This report focuses on Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Molecular Chlamydia Trachomatis (CT) & Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Pcr
In Situ Hybridization
Chips And Microarrays
Isothermal Nucleic Acid Amplification Technology (Inaat)
Mass Spectrometry
Sequencing
Transcription Mediated Amplification
Segment by Application
Hospital
Research
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Cepheid
Beckton Dickinson
Gen Probe (Hologic)
Qiagen
Roche
Bayer Healthcare
Dako
Abbott Laboratories
Danaher
Siemens
Sysmex
Grifols
Biomérieux